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Background: Viral infections contribute to morbidity in cystic fibrosis (CF), but the impact of respiratory 
viruses on the development of airway disease is poorly understood. 
Methods: Infants with CF identified by newborn screening were enrolled prior to 4 months of age to 
participate in a prospective observational study at 4 centers. Clinical data were collected at clinic visits 
and weekly phone calls. Multiplex PCR assays were performed on nasopharyngeal swabs to detect res- 
piratory viruses during routine visits and when symptomatic. Participants underwent bronchoscopy with 
bronchoalveolar lavage (BAL) and a subset underwent pulmonary function testing. We present findings 
through 8.5 months of life. 
Results: Seventy infants were enrolled, mean age 3.1 ±0.8 months. Rhinovirus was the most prevalent 
virus (66%), followed by parainfluenza (19%), and coronavirus (16%). Participants had a median of 1.5 viral 
positive swabs (range 0–10). Past viral infection was associated with elevated neutrophil concentrations 
and bacterial isolates in BAL fluid, including recovery of classic CF bacterial pathogens. When antibiotics 
were prescribed for respiratory-related indications, viruses were identified in 52% of those instances. 
Conclusions: Early viral infections were associated with greater neutrophilic inflammation and bacterial 
pathogens. Early viral infections appear to contribute to initiation of lower airway inflammation in infants 
with CF. Antibiotics were commonly prescribed in the setting of a viral infection. Future investigations 
examining longitudinal relationships between viral infections, airway microbiome, and antibiotic use will 
allow us to elucidate the interplay between these factors in young children with CF. 
© 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. 
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a1. Introduction 
Cystic fibrosis (CF) lung disease begins in the first months of life
with lower airway inflammation, airflow limitation and structural
abnormalities on chest CT [ 1–4 ]. Historically, airway inflammation
has been attributed to bacterial infection, though viral infections∗ Corresponding author at: Department of Pediatrics, University of Nebraska 
Medical Center, Children’s Hospital and Medical Center Omaha, 984220 Nebraska 
Medical Center, Omaha, NE 68198-4220, United States. 
E-mail address: ashley.deschamp@unmc.edu (A.R. Deschamp). 
1 These authors were at Indiana University School of Medicine, Riley Hospital for 
Children at Indiana University Health at the time of the study. 
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ore, evidence of structural airway disease including bronchiecta-
is has been reported in infants with CF, even in the absence of
acterial pathogens [ 4 ]. These findings suggest other factors, such
s viral infections, may initiate the inflammation, chronic infection
nd progressive lung disease characteristic of CF lung disease. 
Infection with respiratory viruses is linked to acute clinical de-
erioration in children with CF [ 5 , 7 ]. Compared to healthy coun-
erparts, infants with CF acquire viral infections with a simi-
ar frequency, but are at greater risk for more prolonged, severe
ower respiratory tract symptoms [ 5 , 8 ] and persistent lower air-
ay obstruction [ 8 ]. Infants with CF hospitalized for viral infections
ave greater pulmonary inflammation, based on higher neutrophil,eserved. 
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s  nterleukin-8 (IL-8) and neutrophil elastase (NE) concentrations in
ronchoalveolar lavage (BAL) fluid compared to controls [ 9 ]. Viral
nfection in school-aged children with CF leads to declining forced
xpiratory volume in one second (FEV 1 ) values [ 10 ], and rhinovirus
nfection specifically is a risk factor for failure to recover FEV 1 fol-
owing pulmonary exacerbation [ 11 ]. Viral infections in children
ith CF have been associated with new acquisition of common
acterial pathogens including Haemophilus influenzae , Streptococcus
neumoniae , and Moraxella catarrhalis [ 6 ], and severe viral infec-
ions requiring hospitalization have been linked to early infection
ith Pseudomonas aeruginosa [ 9 ]. Antiviral interventions, such as
alivizumab, reduce the rate and length of hospitalization due to
SV infection in CF infants [ 12 ]; however, have shown no differ-
nce in age at first acquisition of P. aeruginosa or S. aureus [ 13 ]. 
Healthy infants are typically treated conservatively with obser-
ation and supportive care until viral-induced symptoms resolve;
owever, management decisions for an infant with CF may be
ore complex. Understanding how respiratory viruses contribute
o the early acquisition or evolution of bacterial flora in the CF
irway could lead to modifications in immunization strategies and
reatment decisions. 
We hypothesized that viral infections alter the bacterial flora
nd inflammatory profile in the airway and contribute to the de-
elopment of pulmonary disease in infants with CF. We describe
he frequency of respiratory viral infections in infants with CF and
xplore potential sequelae, including their association with respi-
atory symptoms, airway inflammation, bacterial colonization, and
ulmonary function measures. We also examine antibiotic pre-
cribing patterns in the setting of viral illnesses. 
. Methods 
Participants were enrolled at four sites, Riley Hospital for Chil-
ren (Indianapolis, USA); St. Louis Children’s Hospital (St. Louis,
SA); Princess Margaret Hospital for Children (Perth, Australia);
nd Royal Children’s Hospital (Melbourne, Australia). Study ap-
roval was obtained from the regulatory boards at each institu-
ion. Written informed consent was obtained from parents prior to
nrollment. 
All participants were identified through newborn screening and
nrolled by 4 months of age. Inclusion criteria included a diagnosis
f CF based on sweat chloride levels > 60 mEq/L or two pathogenic
ystic fibrosis transmembrane conductance regulator (CFTR) vari-
nts. Exclusion criteria included the inability to successfully or
afely perform study visits. 
Study visits were scheduled at 1 to 3-month intervals, coor-
inating with routine clinic appointments. A history and physical
xamination were performed at visits. Parents were contacted
eekly via telephone to assess for new respiratory symptoms using
 standardized questionnaire (Online supplement). Nasopharyngeal
NP) swabs were obtained at research clinic visits, and when
articipants were symptomatic, the parents collected a nasopha-
yngeal swab at home (FLOQSwabs TM and UTM TM Viral Transport
edia, COPAN Diagnostics, Murrieta, CA). Parents were trained
n collection techniques by research personnel in clinic (Online
upplement). Viral analysis was performed at the Special Projects
aboratory at Washington University. Respiratory virus polymerase
hain reaction (PCR) was performed using the GenMark eSensor
espiratory Viral Panel (GenMark Diagnostics Inc. Carlsbad, CA). 
Infant pulmonary function testing (PFT) was performed in a
ubset of infants using the raised volume technique coupled with
lethysmography [ 14 , 15 ]. Bronchoscopy with lavage was performed
n a different day, < 4 weeks apart as per protocol. If bronchoscopy
as performed for pulmonary symptoms during that time frame,
he research protocol for BAL fluid collection was followed. Inflam-
atory mediators, including tumor necrosis factor alpha (TNF)-, IL-1 β , and IL-8, were analyzed using commercially available
andwich enzyme immunoassays according to the manufacturer’s
ecommended protocols (R&D Systems, Minneapolis, MN). Func-
ional activity of NE was measured using a specific peptide chro-
ogenic substrate (Elastin Products, Owensville, MO). The urea di-
ution method was used to determine cell counts and cytokine
oncentrations in the epithelial lining fluid (ELF) [ 16 ]. For our anal-
ses, classical CF pathogens were defined as: Haemophilus influen-
ae, methicillin-resistant (MRSA) and -sensitive (MSSA) Staphylo-
occus aureus, Pseudomonas aeruginosa, and Stenotrophomonas mal-
ophilia . Clinical treatment decisions were left to the discretion of
he treating physician. Study data were collected and managed us-
ng REDCap electronic data capture tools [ 17 ] hosted at the Indiana
linical and Translational Sciences Institute. 
.1. Statistical analysis 
Analyses were performed evaluating the infants enrolled in
he prospective, longitudinal study following these children dur-
ng the first year of life. For this report, we established a cut-off
f 260 days of age to include available physiologic measures and
 standard time period for tracking viral and symptom data. The
ata were analyzed cross-sectionally, using the longitudinal data.
or analyses, participants were divided into two groups, “never
irus” and “any virus” for each of the respective endpoints (infant
FT, bronchoscopy, or 260 days of age). Infant height and weight z-
cores were generated using the WHO age adjusted algorithm [ 18 ].
Comparisons were performed using Student’s t -tests for con-
inuous variables, with log-transformations or Wilcoxon-Kruskal- 
allis tests when the data were skewed, and Chi-Square tests for
ategorical variables, with Fisher’s Exact tests when cell counts
ere small. Generalized Linear Models (GLMs) were run when in-
luding covariates, to control for possible confounding effects, in-
luding age and site. Generalized Estimating Equations (GEEs) were
erformed with observation level data, to account for the intra-
articipant correlation present with repeated measures. GEEs al-
owed for the use of covariates, and models were run unadjusted
nd adjusted for age and site. Age and site were weakly associated,
nd so models were run with only one at a time and then together
o ensure collinearity was not an issue. GEE models were also uti-
ized as they allow non-normally distributed data to be used and
erform for both continuous and binary endpoints. Analyses were
one using SAS v9.4 (SAS Institute, Cary, NC) with p -values < .05
eing considered statistically significant. 
. Results 
.1. Participant characteristics 
Participants were screened from May 2013 to December 2016.
t the time of this analysis, 109 participants were screened, 75
ere enrolled and 70 included for analysis (20 from the US and
0 from Australia) (Fig. 1 online supplement). A total of 467 NP
wabs were tested, median 6 NP swabs per participant (range 1–
1). Total swabs tested did not differ by country ( p = .12). Segre-
ation of participants based on viral infection, “any virus” ( n = 53)
ersus “never virus” ( n = 17) through 260 days of age is outlined
n Table 1 . Groups did not differ in age, race, height, weight, CFTR
enotype or environmental exposures. However, at enrollment the
ny virus group had significantly more males ( p = .02). 
.2. Viral detection and respiratory symptoms 
Fifty-three (76%) participants had at least one positive swab
median 1.5, range 0–10). Viral detection was similar across study
ites. Human rhinovirus (HRV) was the most frequently detected
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Table 1 
Baseline demographic and clinical characteristics of the viral infection cohorts. 
Entire cohort ( n = 70) Never virus ( n = 17) Any virus ( n = 53) p -Value 
Age at enrollment (months) 3.0 (0.8) 3.0 (0.5) 3.0 (0.9) .92 
Sex (Male) 29 (41.4) 3 (17.7) 26 (49.1) .02 
Race (Caucasian) 68 (97.1) 17 (100) 51 (96.2) .72 
Weight at enrollment (kg) 5.52 (0.98) 5.44 (0.74) 5.54 (1.05) .70 
Weight at enrollment (z-score) −0.82 (1.18) −0.75 (1.08) −0.84 (1.22) .78 
Height at enrollment (cm) 59.18 (4.47) 59.59 (2.29) 59.04 (5.02) .55 
Height at enrollment (z-score) −0.63 (1.68) −0.23 (0.94) −0.76 (1.86) .14 
CF genotype 
- F508 heterozygous 28 (40.0) 5 (29.4) 23 (43.4) .46 
- F508 homozygous 40 (57.1) 11 (64.7) 29 (54.7) 
-Other 2 (2.9) 1 (5.9) 1 (1.9) 
Smoke exposure ( n = 67) 14 (20.9) 3 (17.7) 11 (22.0) .70 
Day Care ( n = 67) 1 (1.5) 0 (0) 1 (2.0) .56 
Feeding ( n = 62) 
Any breast feeding 36 (58.1) 11 (73.3) 25 (53.2) .17 
Values are means (standard deviation) for continuous variables and frequency (percent) for categorical variables. 
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b  virus, found at least once in 66% of participants. Parainfluenza
virus, coronavirus, RSV and human metapneumovirus (HMPV)
were detected in 19%, 16%, 9% and 7% of participants, respectively
( Table 2 ). Viral co-infection was detected in 11% of participants
( n = 8). Viral positivity was not significantly affected by who col-
lected the NP swab, research personnel versus parents. 
The median (IQR) rate of any recorded respiratory symptom for
our participants was 26% (0–90%). The most commonly reported
symptoms were cough and nasal congestion, reported at 15% (0–
59%) and 17% (0–86%) of encounters. Cough and nasal congestion
were associated with a greater likelihood of virus detection (OR
1.15, 95% CI 1.06–1.26 and OR 1.15, 95% CI 1.04–1.27, respectively)
( Table 3 ). Wheezing, fever, altered breathing and decreased activity
level were also reported, but not significantly related to viral pos-
itivity. Overall, 21% of the swabs collected in asymptomatic par-
ticipants were positive for a virus; this occurred at least once in
34% ( n = 24) of participants. In the absence of symptoms, the pro-
portion of swabs positive for HRV (21%) or coronavirus (31%) was
higher than for the other viruses tested (7%), p < .01. Overall, 11 in-
fants received palivizumab for RSV prophylaxis before the age of
one, all from the US. However, there were no differences in the
rates of RSV between continents (US 2/20 vs AUS 4/50, p = .29). 
There were 21 hospitalizations for respiratory indications in
18 participants. The median age at first hospitalization was
3.3 months (range 0–8 month). Of the 21 hospitalizations, a NP
swab was collected within 7 days of hospitalization in 13. Eleven
(85%) were positive for a respiratory virus. Viruses included rhi-
novirus ( n = 5), RSV ( n = 2), influenza ( n = 1), parainfluenza ( n = 1),
human metapneumovirus ( n = 1), and co-infection with adenovirus
and human metapneumovirus ( n = 1). Hospitalization rates did notTable 2 
Respiratory viruses detected from nasopharyngeal samples collected from infants 
through 260 days of age. 
NP swabs ( n = 467) Overall prevalence ( n = 70) 
Never virus 310 (66%) 17 (24%) 
Any virus 157 (37%) 53 (76%) 
Rhinovirus 110 (24%) 46 (66%) 
Parainfluenza virus 21 (4%) 13 (19%) 
Coronavirus 17 (4%) 11 (16%) 
Respiratory syncytial virus 12 (3%) 6 (9%) 
Human metapneumovirus 9 (2%) 5 (7%) 
Influenza virus 1 ( < 1%) 1 (1%) 
Adenovirus 2 ( < 1%) 1 (1%) 
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l  iffer between US and Australian sites nor between the “never
irus” and “any virus” groups (data not shown). 
.3. Respiratory viruses, pulmonary inflammation, and bacterial 
solates 
Bronchoscopy with BAL was performed in 68 infants; 66 had
ufficient data for analyses (mean age 4.2 ±1.6 months). Partici-
ants in the “any virus” group ( n = 22) were significantly older
han the “never virus” group ( n = 44), 5.1 ±1.9 month and 3.8 ±1.2
onth, respectively ( p < .01). There was no significant difference in
ex between the groups at time of bronchoscopy. Three of the 66
nfants had pulmonary symptoms reported at time of BAL. For the
ny virus group, the median time between last detected virus and
ronchoscopy was 24 days (range 0–89). The median time between
ast NP swab and bronchoscopy was 3 days (IQR 1–12 days). Lavage
bsolute neutrophil counts were higher in participants with pre-
ious viral infection (2.3 ×10 5 vs. 1.1 ×10 5 cells/mL ELF) in both
nadjusted analyses ( p = .01) and adjusted for age at time of BAL
 p = .02) ( Fig. 1 , panel A). There was no relationship between prior
irus detection and current inflammatory markers in BAL (TNF- α,
L-1 β , IL-8, NE). 
Detection of a virus before BAL was associated with bacterial
rowth (45% in the “never virus group” vs 77% in the “any virus”
roup, p = .02) and the isolation of classic CF bacterial pathogens
rom BAL fluid (5% in the “never virus” group vs 32% in the “any
irus” group, p = .01) ( Table 4 ). P. aeruginosa was isolated from
AL fluid in only one participant ( Table 4 ). Adjusting analyses to
ccount for a viral infection in close proximity to the time of
ronchoscopy (within 7 days) did not alter these results (data not
hown). 
The presence of classic pathogens in BAL fluid was in turn asso-
iated with greater pulmonary inflammation, with higher concen-
rations of NE ( p < .01) and IL-8 ( p < .01) when compared to those
ith “no growth” or “oropharyngeal flora only” (Fig. 2, panel B on-
ine supplement). Oropharyngeal swab data available in online sup-
lement (Fig. 3, Table 1 online supplement). 
.4. Antibiotic prescriptions and viral infections 
Administration of prophylactic anti-staphylococcal antibiotics in
arly infancy is standard practice at the Australian centers. All Aus-
ralian participants were treated with amoxicillin-clavulanate dur-
ng the study time period. All but three were started on prophy-
axis prior to BAL and the remaining three were started shortly
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Table 3 
Respiratory symptoms associated with viral infections in infants with cystic fibrosis. 
Overall a Never virus ( n = 17) Any virus ( n = 53) p -Value ∗ Odds ratio of detecting a Virus ∗∗ p -Value ∗∗
No symptoms 74% (10 −100) 83% (10–100) 70% (24–96) .06 Reference N/A 
Any symptom 26% (0–90) 17% (0–90) 30% (4–76) .06 1.26 (1.16–1.37) < .01 
Cough 15% (0–59) 8% (0–41) 16% (25–59) .06 1.15 (1.06, 1.26) < .01 
Nasal congestion 17% (0–86) 8% (0–86) 19% (33–59) .04 1.15 (1.04, 1.27) < .01 
Wheeze 4% (0–65) 0% (0–14) 4% (0–65) .09 0.99 (0.89, 1.10) .84 
Fever 0% (0–9) 0% (0–5) 0% (0–9) .15 1.30 (0.99, 1.69) .06 
Altered breathing 0% (0–15) 0% (0–15) 0% (0–14) .11 1.16 (0.98, 1.37) .08 
Decreased activity 0% (0–28) 0% (0–15) 0% (0–28) .19 0.93 (0.80, 1.07) .30 
For each additional Symptom Reported 1.10 (1.06–1.15) < .01 
a Median (25th–75th) rate of symptom reporting over all encounters through 8 months of age. 
∗ p -Values from Wilcoxon rank-sum tests. 
∗∗ Analyses were performed using GEE models with repeated measures, adjusted for the presence of other symptoms. 
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sfter BAL. New antibiotic courses were defined as new pre-
criptions for respiratory related indications, including respiratory
ymptoms, otitis media, and/or bacterial eradication. During the
rst 260 days of life, infants in the US were prescribed more
ourses of systemic antibiotics (median 2, 0–7) for any indica-
ion versus Australian infants (median 0, 0–3) ( p < .01). Moreover,
merican infants received more antibiotic courses related specifi-
ally to new respiratory symptoms (median 1, 0–5) than Australian
nfants (median 0, 0–3) ( p < .01) and for all respiratory-related
ndications (US median 1.5, 0–7 and Australia median 0, 0–3)
 p < .01). When viral testing was performed within 7 days of start-
ng new antibiotics for respiratory indications, a virus was detectedig. 1. Inflammatory cells and soluble inflammatory markers in lavage fluid (BALF) collect
hown. Any virus ( n = 22); Never virus ( n = 44). n 56% ( n = 15) and 47% ( n = 7) of cases in the US and Australia,
espectively ( p = .75) (Fig. 4 online supplement). Twenty-four par-
icipants (66%) were prescribed a new antibiotic any time before
AL. After adjusting for continents, infants who had ever received
ystemic antibiotics, irrespective of anti-staphylococcal prophylaxis,
ad higher neutrophil elastase ( p < .01) and TNF- α ( p < .01) con-
entrations in BAL fluid than those who had not. Of the nine in-
ants who had classic CF pathogens detected on BAL, one was
tarted on antibiotics in response to the lavage findings. Six infants
ere already on antibiotics at the time of BAL, one for pneumonia,
hree for a cough, one for otitis media and one for results from a
rior surveillance oropharyngeal culture. ed from infants during the study period. Raw data is plotted and p -values < .05 are 
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Table 4 
Microbial isolates and their association with viral infections in infants with cystic 
fibrosis. 
Never virus 
( n = 44) 
Any virus 
( n = 22) 
p -Value p -Value † 
No growth 23 (52) 5 (23) .03 .04 
Oropharyngeal flora 18 (41) 15 (68) .07 .05 
Any bacterial growth 20 (45) 17 (77) .02 .02 
Any classic CF pathogen 2 (5) 7 (32) .01 .01 
- Haemophilus influenzae 1 (2) 1 (5) 1.0 .56 
- Methicillin susceptible 
Staphylococcus aureus 
0 (0) 4 (18) .01 UTC 
-Methicillin resistant 
Staphylococcus aureus 
0 (0) 1 (5) .33 UTC 
-Pseudomonas aeruginosa, 
non-mucoid 
0 (0) 1 (5) .33 UTC 
-Stenotrophomonas 
maltophilia 
1 (2) 0 (0) 1.0 UTC 
Moraxella catarrhalis 0 (0) 2 (9) .11 UTC 
Escherichia coli 2 (5) 1 (5) 1.0 .96 
Klebsiella pneumoniae 0 (0) 1 (5) .33 UTC 
Pseudomonas putida 1 (2) 0 (0) 1.0 UTC 
Morganella morganii 0 (0) 1 (5) .33 UTC 
Enterobacter cloacae 1 (2) 1 (5) 1.0 .64 
Any fungal growth 2 (5) 3 (14) .32 .20 
Candida albicans 2 (5) 3 (14) .32 .20 
Values are frequencies (percentages) with p -values from Fisher’s Exact Test and 
from generalized linear models (GLM) † adjusting for age at time of BAL (conti- 
nent was highly correlated with age). There was no difference in sex at time of 
bronchoscopy. UTC = unable to calculate. 
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t3.5. Respiratory virus detection and infant pulmonary function 
measures 
Twenty-eight participants successfully completed infant pul-
monary function testing (mean age 4.8 ±1.3 month), 10 (36%)
“never virus” and 18 (64%) “any virus.” There was no difference in
age ( p = .11), sex, or any pulmonary function measure between par-
ticipants in the “never virus” vs “any virus” groups (Table 2 online
supplement). 
4. Discussion 
While respiratory viral infections are common in infancy, their
impact on CF lung disease is largely unknown. In this study, viral
infections were associated with increased airway inflammation and
more bacterial isolates, including classic CF bacterial pathogens
in the lower airway. In turn, the presence of those classic CF
pathogens was also associated with increased NE and IL-8 in the
lower airways. Human rhinovirus was the most common virus de-
tected, isolated more frequently in those with symptoms including
cough and nasal congestion. In 52% of cases where antibiotics were
prescribed for respiratory-related indications, a virus was detected.
Our finding of human rhinovirus being the most commonly de-
tected virus agrees with recent publications showing a high preva-
lence of HRV in early life, both in healthy children and those with
CF [ 19–21 ]. Older studies commonly report RSV, influenza and ade-
novirus in the youngest populations, detected using immunofluo-
rescence staining or virus isolated from tissue or respiratory secre-
tions [ 8 , 9 ]. Indeed, these differences in viral prevalence between
studies can be explained by the advent and use of PCR assays as
a sensitive diagnostic tool for respiratory viruses. Furthermore, in
our study, samples were collected in outpatient settings, either in
clinic or at home. Eighteen participants (26%) were hospitalized
for respiratory illnesses during our study. This is similar to pre-
vious studies in which CF infants hospitalized with viral infections
ranged from 23 to 39% [ 8 , 9 ]. 
We show 1–2 respiratory viruses identified during the first
8 months of life (median 1.5), consistent with community-basedirth cohorts with 2–5 acute respiratory illnesses during infancy
 19 ]. The percentage of viral positive swabs in our study was 37%.
rior studies in healthy infants show a wide range of viral posi-
ivity, anywhere from 23% [ 23 ] to 69% [ 19 ]. Comparing to studies
xamining viruses in the first year of life [ 19 , 20 , 22 , 24 ], we found
omparable findings as in those studies viral positivity ranged from
7% [ 24 ] to 69% [ 19 ] in healthy infants. Our rates of detection in
ome versus clinic collected samples were not significantly dif-
erent. This method of parental collection has been successfully
sed in prior studies. One study performed in the emergency room
howed parental collected samples were equivalent to physician
ollected samples [ 25 ]. Others have demonstrated success with
arents collecting samples at home and then mailing swabs to
tudy coordinators [ 26 , 27 ]. One study did report mold in mailed
amples [ 28 ]; however, these samples, unlike ours, were not main-
ained as frozen during storage and shipping. Home sampling by
arents provides feasibility for frequent and/or rapid sampling
t the onset of symptoms, without the barriers of participants
oming into clinic or research coordinators going to participants’
omes. 
Unsurprisingly, viral detection was higher in our participants
ho were symptomatic, most often cough and nasal congestion.
his is consistent with commonly reported viral symptoms in other
F cohorts [ 5 , 7 ]. Increased lower respiratory tract symptoms have
een reported with HRV infection, especially in infants who have
nderlying lung diseases such as CF [ 5 , 7 ]. In our cohort, lower res-
iratory involvement, evidenced by wheezing, was reported exclu-
ively in the any virus group. However it was infrequently reported
nd no significant difference was detected between groups. Our
ndings highlight the important role of viruses as a cause of early
F respiratory symptoms. 
Bacterial pathogens are an important factor in the evolution of
F pulmonary disease. Through early surveillance, pathogens in the
ower airway in infants with CF have been linked to inflammation
nd pulmonary function decline [ 1 , 2 , 29 ]. We found viral infection
as associated with higher concentrations of lavage neutrophils
s well as the presence of bacterial isolates, including classic CF
athogens. These pathogens were associated with higher NE and
L-8 concentrations in BAL, consistent with previous studies [ 1 , 3 , 4 ].
ased on our protocol, bronchoscopy was typically performed dur-
ng a time of clinical stability and not during an acute viral infec-
ion. This may explain why there was less of a significant inflam-
atory response detected in the any virus group. However bacteria
resent in the lower airways clearly had more of an inflammatory
ffect, as would be expected. 
In our participants, we found early viral infection was linked
o lower airway bacterial isolates, with an increased incidence of
lassic CF bacterial pathogens. This contrasts with previous re-
orts showing no changes in colonization or infection with typ-
cal CF pathogens following viral infection [ 6 , 30 ]. Of note, these
tudies primarily involved school-aged children who underwent
AL to detect viruses [ 6 , 9 ]. We obtained nasopharyngeal swabs
o detect viruses and BAL to detect bacterial pathogens which
ay contribute to the difference in findings. There are several
ines of evidence to support a mechanistic link between viral
nfections and lower airway bacterial colonization. Viral infec-
ions can damage the epithelial barrier, thus facilitating binding
nd translocation of bacteria into the airway [ 31 , 32 ]. In addition,
iruses can decrease bacterial clearance contributing to the per-
istence of bacteria within the airway [ 33 ]. In COPD, rhinovirus
pecifically has been shown to impair bacterial phagocytosis by
acrophages [ 34 ]. Others, using in vitro experiments, have shown
lveolar macrophages are less able to mount an immune response
o bacteria following HRV infection [ 35 , 36 ]. Viruses clearly play a
ole in the airway, the most significant of which may be their in-
eraction with immune defense and bacteria. 
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 Lastly, we examined antibiotic use in this young cohort of in-
ants with CF. In contrast to the standard practice of watchful wait-
ng and supportive care in non-CF infants with viral infections, the
hoice to use antibiotics in young children with CF with respira-
ory viral infections is more complicated. On one hand, we have
o consider antibiotic stewardship [ 37 , 38 ], along with the poten-
ial effects antibiotics have on commensal organisms and the de-
eloping microbiome [ 39–41 ], and the growing sensitivity among
linicians regarding the use of antibiotics in CF care for symptoms
hat do not meet the clinical criteria of a pulmonary exacerbation
 42 ]. These issues are juxtaposed by the potential benefits antibi-
tic treatment may have for the individual. For example the treat-
ent or prevention of concurrent or subsequent bacterial infec-
ion, bacteria that may be linked to a poorer long-term prognosis
 1 , 2 , 29 ]. Our data show a virus was present in roughly half of all
nstances in which a physician decided to start a new course of
ntibiotics; however bacterial cultures were not routinely collected
t or after these events. Therefore, we are limited in our ability to
ddress the potential benefits or detriments of these treatment de-
isions. These questions, particularly in infants and young children
ith CF, would benefit greatly from further investigation. 
This study has several limitations. First, very few individuals
ad detected early episodes of RSV, HMPV or influenza, limiting
ur ability to specifically investigate the effects of each individ-
al virus. A relatively small number of viral infections occurred in
articipants during the first 8 months of life (median 1.5). There-
ore, we divided the groups into “never virus” and “any virus.”
e assumed participants did not have viruses before enrollment
n the “never virus” group, unless medical history indicated oth-
rwise. It is possible that individuals with prior or undetected vi-
al infections were included in the “never virus” group(s). As we
id not have physiologic measures prior to any viral infection, we
ere unable to assess whether children with more severe lung dis-
ase were more likely to be symptomatic with a virus or possi-
ly the reverse. Also, per the study design, the majority of the NP
wabs were collected when infants were symptomatic. Therefore,
e could not accurately estimate asymptomatic carrier rates. Some
nfants completed their bronchoscopy and infant PFT visits within
 month of enrollment, limiting the viral data available prior to and
etween these visits. This short observation period may have influ-
nced our results. Only a subset of participants was able to com-
lete pulmonary function testing, yielding a low number of par-
icipants for that analysis. This small sample size may have con-
ributed to the lack of statistically significant differences between
roups. Lastly, we did not have a control group due to the na-
ure of the study protocol which included bronchoscopy and in-
ant lung function testing, sedated procedures that would not be
lectively performed on healthy infants. However, there are mul-
iple epidemiologic studies of viral infections in healthy infants to
hich our prevalence results are comparable [ 19 , 20 , 22 , 24 ]. 
. Conclusions 
Viral infections in CF infants do not appear to be more fre-
uent than those reported in healthy controls, however are asso-
iated with significant changes in the lower airway, including neu-
rophilic inflammation and greater frequency of classic CF bacterial
solates. Systemic antibiotics were prescribed in symptomatic par-
icipants, more than half (52%) in the setting of a viral infection.
uture studies examining the relationship between viral infection,
ntibiotic use, and the airway microbiome over time will allow
s to better understand these interactions and identify appropriate
nterventions. cknowledgments 
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